公开(公告)号：US20230212249A1

公开(公告)日：2023-07-06

申请号：US18068506

申请日：2022-12-19

Applicant: YUHAN CORPORATION

Inventor： Byung Hyun CHOI ,  In Hwan LIM ,  Jun Young PARK ,  Jin Hyoung LEE ,  Ki Hong KIM ,  Hae Yong JO ,  Jun Hwan KIM ,  Moo Young SONG ,  Jong Gyun KIM

IPC: C07K14/605 ,  C12P21/02 ,  C07K14/50 ,  C07K19/00 ,  C07K16/46 ,  C12N5/00 ,  C12N15/00

CPC classification number: C07K14/605 ,  C12P21/02 ,  C07K14/50 ,  C07K19/00 ,  C07K16/46 ,  C12N5/00 ,  C07K2319/30 ,  C12N15/00

Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

公开(公告)号：US20210188936A1

公开(公告)日：2021-06-24

申请号：US16606279

申请日：2018-04-20

Applicant: YUHAN CORPORATION

Inventor： Byung Hyun CHOI ,  In Hwan LIM ,  Jun Young PARK ,  Jin Hyoung LEE ,  Ki Hong KIM ,  Hae Yong JO ,  Jun Hwan KIM ,  Moo Young SONG ,  Jong Gyun KIM

IPC: C07K14/605 ,  C07K14/50 ,  C12P21/02

Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

公开(公告)号：US20210087268A1

公开(公告)日：2021-03-25

申请号：US16970351

申请日：2019-02-28

Applicant: YUHAN CORPORATION

Inventor： Kwang-Hoon LEE ,  June Hyung LEE ,  Na Rae LEE ,  Eunjeong JEONG ,  Young Bong PARK ,  Nakho CHANG ,  Eun-Jung LEE ,  Ki Hong KIM ,  Sunghyun CHOI ,  Byung Hyun CHOI ,  Ju Young PARK ,  Moo Young SONG ,  Jong-Seo LEE ,  Kyu-Tae KIM ,  Bong-Kook KO

IPC: C07K16/28

Abstract: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition.
The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.

公开(公告)号：US20250066487A1

公开(公告)日：2025-02-27

申请号：US18935875

申请日：2024-11-04

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Yeryoung YONG ,  Ui-Jung JUNG ,  Hyejin CHUNG ,  Kyeongsu PARK ,  Wonjun SON ,  Yangsoon LEE ,  Yeunju KIM ,  Eunsil SUNG ,  Youngkwang KIM ,  Youngdon PAK ,  Minji PARK ,  Jaehyun EOM ,  Hyoju CHOI ,  Moo Young SONG ,  Na Rae LEE ,  Young Bong PARK ,  Eun-Jung LEE ,  Eun-Jung LEE

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US20210221869A1

公开(公告)日：2021-07-22

申请号：US17256296

申请日：2019-07-24

Applicant: YUHAN CORPORATION ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

Inventor： Moo Young SONG ,  Taejin YOON ,  Jung-Sun LEE ,  Byung Hyun CHOI ,  In Hwan LIM ,  Man Sil PARK ,  Jin-Hyoung LEE ,  Hyoung Sig SEO ,  Hyeon Woo KANG ,  Sung Ho KIM ,  Eun Jig LEE ,  Jin Sook YOON ,  Cheol Ryong KU

IPC: C07K14/72

Abstract: Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.

公开(公告)号：US20190314452A1

公开(公告)日：2019-10-17

申请号：US16348249

申请日：2017-11-10

Applicant: YUHAN CORPORATION

Inventor： Han Na HONG ,  Jun Hwan KIM ,  Hyun Ho CHOI ,  Dohoon KIM ,  Taewang KIM ,  Se Woong OH ,  Moo Young SONG ,  Jong Gyun KIM

IPC: A61K38/18 ,  A61K38/26 ,  A61K38/17 ,  A61P1/16

Abstract: The present invention provides a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. Specifically, the present invention provides a fusion protein comprising a biologically active protein and an FGF21 mutant protein; and a pharmaceutical composition containing the fusion protein, which is effective for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. A pharmaceutical composition of the present invention has the effect of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used as a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.